Results of cell viability, metabolic activity, and pro-inflammatory gene expression level showed that the AM materials cross-linked with carbodiimide in the presence of different types of amino acids are well tolerated without evidence of detrimental effect on cell growth.
Overall, these approaches have proven relatively safe and are well tolerated, although evidence for clinical effectiveness in controlled trials is still lacking [1], [4], [5], [10].
Bilastine treat-ment was well tolerated without evidence of increased sedation with dose escala-tion.
Treatment with PX-866 and docetaxel was well tolerated, without evidence of overlapping/cumulative toxicity.
All drugs were well tolerated, without evidence of toxicity or major side-effects.
Overall, intravenous administration of ACZ885 up to 10 mg/kg given twice with 14 days between dosing was found to be well tolerated without evidence of immunogenicity.
In patients with mild to moderate active lupus, 360 mg/m2 epratuzumab was well tolerated, with evidence of clinical improvement after the first infusion and durable clinical benefit across most body systems.
The starting dose of 1 mg/m was derived from single and repeat dose toxicity studies and represented one sixth of 0.3 mg/kg (6 mg/m), a dose tolerated without evidence of serious, irreversible or life-threatening toxicity in the most sensitive of the two species tested.
Phase I data [ 46] showed that blocking the PD-1 immune checkpoint with a targeted antibody may be safe and well tolerated with evidence of anti-tumor activity, presumably through immunogenic mechanisms as PD-1 receptors are not expressed on non-hematologic malignancies.
Recently, a human anti-CCL2 IgG1 κ monoclonal antibody (mAb), carlumab (CNTO 888), has demonstrated to be well tolerated with evidence of transient free CCL2 suppression and preliminary antitumor activity in a phase I study of 44 patients with solid tumors [ 118].
